Blogger's Note: requires registration (free) to view
Clinical Care Options - Oncology CME - OCEANS: PFS Improvement of 4 Months With the Addition of Bevacizumab to Carboplatin/Gemcitabine in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
CCO Independent Conference Coverage of the 2011 American Society of Clinical Oncology Annual Meeting*
*CCO is an independent medical
education company that provides state-of-the-art medical information to
healthcare professionals through conference coverage and other
educational programs.
OCEANS: PFS Improvement of 4 Months With the Addition of Bevacizumab to Carboplatin/Gemcitabine in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
Posting Date: June 15, 2011- OCEANS: randomized, double-blind, placebo-controlled phase III trial[1]
Summary of Key Conclusions
- Addition of bevacizumab to carboplatin/gemcitabine yielded
significant benefits vs carboplatin/gemcitabine alone in patients with
platinum-sensitive recurrent ovarian cancer
- Median PFS improved by 4 months
- Objective response improved by 21%
- Median duration of response improved by 3 months
- Trend toward improved OS
- Data not yet mature
- Safety profile of bevacizumab plus carboplatin/gemcitabine consistent with previous reports
- No new safety signals observed
- No gastrointestinal (GI) perforations reported
Background
- Carboplatin/gemcitabine US Food and Drug Administration approved in 2006 for treatment of platinum-sensitive recurrent ovarian cancer based on improvement in PFS vs carboplatin alone in phase III clinical trial[2]
- Bevacizumab: humanized anti-VEGF monoclonal antibody
- Demonstrated single-agent activity in recurrent ovarian cancer[3,4]
- Current study assessed carboplatin/gemcitabine chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer...............cont'd
